Anti-CD20 antibody therapy for B-cell lymphomas

N Engl J Med. 2012 May 24;366(21):2008-16. doi: 10.1056/NEJMct1114348.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antigens, CD20 / immunology*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Humans
  • Lymphoma, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Practice Guidelines as Topic
  • Prednisone / therapeutic use
  • Rituximab
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol